A new PET scan tracks brain tumors by their appetite for tryptophan
NCT ID NCT07735819
First seen Jul 30, 2026 · Last updated Jul 31, 2026 · Updated 1 time
Summary
This trial is testing whether a special PET/CT scan that uses a radioactive form of tryptophan can provide better information about gliomas (a type of brain tumor) than standard MRI. The study has three parts: seeing if the scan can better define the tumor for radiation planning, distinguishing tumor regrowth from radiation damage, and measuring whether a drug (minocycline) can block a metabolic pathway in low-grade tumors. Adults with newly diagnosed or treated gliomas are eligible.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- a radioactive tracer called [18F]FETrp used in PET/CT scans, and in one arm the drug minocycline is also given
- What this could lead to
- If successful, this imaging method could help doctors more accurately target radiation therapy and distinguish tumor growth from treatment-related changes, potentially improving outcomes for people with brain tumors.
- What could go wrong
- This is a relatively small, early-phase trial, so the imaging technique may not prove superior to MRI. The drug minocycline may cause side effects and may not effectively block the pathway as hoped.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 2
Tests whether the treatment actually works, and watches for side effects, in a larger group.
- Participants
-
About 61 people
The number the study aims to enrol. It can still change while the study runs.
- Expected to start
-
Sep 2026
An estimate. Start dates often move.
- Expected to finish
-
Jun 2031
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
FOR ARMS 1-3 Inclusion Criteria: * Age =18 years. * Patient is able to lie in the PET/CT scanner for at least 60 minutes while undergoing scanning. * Patient is willing and able to review, understand, and provide written consent for the study procedures and indicates that they are aware of the investigational nature of this study. Exclusion Criteria: * Patients who are pregnant or lactating are excluded. Premenopausal women (defined per institutional guidelines) must have a negative pregnancy test (urine or serum) within 7 days of the PET scan. * Severe increased intracranial pressure, status epilepticus, or other severe or progressing clinical symptoms requiring urgent intervention in the opinion of the treating * Karnofsky performance score \<60, as determined by one of the clinician co- investigators. ADDITIONAL CRITERIA FOR ARM 1: Inclusion Criteria: * Histopathology/cytopathological diagnosis of a glioblastoma without a history of radiation. * The tumor is deemed amenable for radiation treatment (pre-radiation planning MRI can be done before or after the PET scan). ADDITIONAL CRITERIA FOR ARM 2: Inclusion Criteria: * Previous histopathology/cytopathological diagnosis of glioblastoma. * History of glioma radiation. * Presence of a new or progressing enhancing brain lesion on follow-up clinical MRI suspicious for post-radiation glioma progression or late radiation-induced MRI changes (i.e., radiation injury), at least 7 mm in bidirectional diameter. * The most recent MRI, used for comparison with the PET/CT, is performed within 4 weeks of the planned PET scan. ADDITIONAL CRITERIA FOR ARM 3 Inclusion Criteria: * MRI diagnosis of a brain tumor, previously verified to be a low-grade (WHO grade 2, IDH (isocitrate dehydrogenase) mutant glioma, based on histopathology from biopsy or resection. * The detected mass on the most recent clinical MRI is at least 7 mm in bidirectional diameter (i.e., twice the PET scanner resolution). * The tumor does not require urgent (within 1 month) resection, steroid treatment, or radiation. * The most recent MRI, used for comparison with the PET/CT, is performed within 4 weeks. * Patient agrees to have a baseline and follow-up PET/CT scan (approximately 1 month later) and interval oral treatment with 200mg/day minocycline. * Due to planned minocycline treatment, patients will need to have adequate renal function Exclusion Criteria: * Active connective tissue disorders, such as lupus or scleroderma. * History of allergic reaction to minocycline or any tetracyclines. * Ongoing treatment with warfarin with INR \> 1.5. * History of colitis during antibiotics treatment.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Glioblastoma are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Karmanos Cancer Institute
Detroit, Michigan, 48201, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- VISTA: valproic acid, irinotecan, and simvastatin for recurrent glioma
- Entacapone combined with bevacizumab in patients with glioblastoma at first recurrence based on the MYOF/p-STAT3 signaling axis: a multicenter, randomized, Double-Blind, Placebo-Controlled study
- One extra radiation dose after standard brain cancer therapy: can it boost the immune system?
- Radioactive tracer lights up Oxygen-Starved brain tumors
- Can a common virus vaccine help fight brain cancer?
- Radioactive tiles target brain tumors in frail patients